Table 1.
Disposition of subjects during the extension study
| Original cinacalceta (n = 334) | Original placebo (n = 255) | |
|---|---|---|
| Enrolled in extension study, n | 334 | 255 |
| Did not receive study medication, n (%) | 1 (<1) | 3 (1) |
| Received study medication, n (%) | 333 (100) | 252 (99) |
| Titration phase—weeks 1–8, n (%) | ||
| Started | 333 (100) | 252 (99) |
| Discontinued | 15 (4) | 18 (7) |
| Completed | 318 (95) | 234 (92) |
| Maintenance phase—weeks 9–32, n (%) | ||
| Started | 318 (95) | 234 (92) |
| Discontinued | 56 (17) | 50 (20) |
| Completed | 262 (78) | 184 (72) |
| Follow-up phase—weeks 33–164, n (%) | ||
| Startedb | 261 (78) | 182 (71) |
| Discontinued | 136 (41) | 103 (40) |
| Completed | 125 (37) | 79 (31) |
| Total discontinued | 209 (63) | 176 (69) |
| Subjects rolled over to extension study, n (%) | ||
| After 6 moc | 236 (71) | 150 (59) |
| After 12 mod | 98 (29) | 105 (41) |
a
All subjects who had 26 to 52 wk of cinacalcet therapy prior to study entry.
b
One original cinacalcet and two original placebo subjects completed maintenance phase and did not start follow-up phase.
c
Subjects completing studies A, B, and C.
d
Subjects completing studies D and E.